RIDE-001
/ Trained Therapeutix Discovery
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
November 07, 2025
Trained Therapeutix Demonstrates RIDE-001 Trains Myeloid Cells for Anti-Tumor Immune Response in Preclinical Data Presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
(GlobeNewswire)
- "The data demonstrated that RIDE-001 effectively induced trained immunity in vitro in primary human immune cells, induced anti-tumor immunity in mouse tumor models of melanoma and colorectal cancer, and safely induced innate immune responses in rats and non-human primates. RIDE-001 showed therapeutic activity against solid tumors as a single agent, and it also exhibited synergy in combination with immune checkpoint inhibition."
Preclinical • Colorectal Cancer • Melanoma
October 03, 2025
RIDE-001: A well-tolerated innate immunotherapy to treat cancer by targeting and reprogramming bone marrow progenitor cells
(SITC 2025)
- "Spurred by its excellent safety profile, Trained Therapeutix has initiated GMP manufacturing of RIDE-001 in anticipation of the first clinical studies in patients with solid tumors. Its successful clinical development is a potential breakthrough for cancer patients who do not benefit from checkpoint inhibition due to myeloid-driven immunosuppression."
Colorectal Cancer • Melanoma • Oncology • Solid Tumor • APOA1
1 to 2
Of
2
Go to page
1